phenoxymethylpenicillin

Small moleculeapproved

Approved

Jan 13, 1958

PENICILLIN V HYDRABAMINE, a semi-synthetic antibiotic, is used for the treatment of mild to moderately severe infections (e.g. dental infection, infections in the heart, middle ear infections, rheumatic fever, scarlet fever, skin infections, upper and lower respiratory tract infections) caused by susceptible, usually gram-positive, organisms. — NCATS

Clinical trial activity

14 trials · 29 clinical orgs · 20 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jan 1, 2009 (NCT00823433)

Timeline

1950s

Jan 13, 1958
Earliest FDA Approval
Jan 13, 1958
American Home Products — Marketing Organization

1960s

Apr 7, 1967
Eli Lilly — Marketing Organization
Jul 3, 1968
Teva — Marketing Organization

1970s

Mar 8, 1971
Apothecon — Marketing Organization
Nov 17, 1971
American Antibiotics — Marketing Organization
Nov 17, 1971
Belcher Pharmaceuticals — Marketing Organization
Aug 7, 1972
Mylan — Marketing Organization
Aug 9, 1974
Pfizer — Marketing Organization
Oct 28, 1976
Puracap Pharmaceutical — Marketing Organization

1980s

Aug 12, 1980
GlaxoSmithKline — Marketing Organization
Nov 23, 1988
DAVA Pharmaceuticals — Marketing Organization
Nov 23, 1988
Strides Pharma Science — Marketing Organization
Nov 23, 1988
Chartwell Pharmaceuticals — Marketing Organization

1990s

Nov 30, 1995
Sandoz — Marketing Organization

2000s

Apr 29, 2008
Aurobindo Pharma — Marketing Organization
Jan 1, 2009
Earliest Phase 1 Sponsor(trial)

2010s

Jan 1, 2013
Earliest Phase 3 Sponsor(trial)
Oct 11, 2013
Hikma — Marketing Organization

2020s

Jan 1, 2023
Earliest Phase 2 Sponsor(trial)

Mechanism of action

Bacterial penicillin-binding proteinINHIBITOR
Bacterial penicillin-binding protein inhibitor
Indicated for streptococcal, pneumococcal and staphylococcal infections

Approval history

approvedJan 13, 1958

Chemistry & pharmacology

Loading structure…

SMILES

CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O

Mol. weight: 350.4 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Delivery: Oral
Availability: Prescription Only

Oral

Yes

Parenteral

Topical

Sources

Also known as

(2s,5r,6r)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1- azabicyclo(3.2.0)heptane-2-carboxylic acid
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1- azabicyclo(3.2.0)heptane-2-carboxylic acid
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
6-phenoxyacetamidopenicillanic acid
6-phenoxyacetamidopenicillanic acid
beepen vk
beepen vk
beepen-vk
beepen-vk
betapen-vk
betapen-vk
fenoximetilpenicilina
fenoximetilpenicilina
ledercillin vk
ledercillin vk
meropenin
oracillin
oracillin
penapar-vk
penapar-vk
penicillin phenoxymethyl
penicillin phenoxymethyl
penicillin phenoxymethyl
penicillin potassium phenoxymethyl
penicillin potassium phenoxymethyl
penicillin v
penicillin v
penicillin v
penicillin v
penicillin v
penicillin v
penicillin v
penicillin v
penicillin vk
penicillin vk
penicillin-vk
penicillin-vk
penicillin v potassium
penicillin v potassium
penicillin v potassium
penicillin v potassium
pen-vee k
pen-vee k
pfizerpen vk
pfizerpen vk
phenomycilline
phenomycilline
phenopenicillin
phenoxomethylpenicillin
phenoxomethylpenicillin
phenoxymethylenepenicillinic acid
phenoxymethylenepenicillinic acid
phenoxymethylpenicillin
phenoxymethylpenicillin
phenoxymethylpenicillin
phenoxymethylpenicillin
phenoxymethylpenicillin
phenoxymethylpenicillin
phenoxymethylpenicillin
phenoxymethyl penicillin
phenoxymethyl penicillin
phenoxymethyl penicillin
phénoxyméthylpénicilline
phénoxyméthylpénicilline
phenoxymethylpenicillinic acid
phenoxymethylpenicillin k
phenoxymethylpenicillin potassium
phenoxymethylpenicillin potassium
phenoxymethylpenicillinum
phenoxymethylpenicillinum
potassium phenoxymethyl penicillin
potassium phenoxymethyl penicillin
pv
pv
uticillin vk
uticillin vk
v-cillin
v-cillin
v-cillin
v-cillin k
v-cillin k
v-cillin-k
v-cillin-k
veetids
veetids

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06295120	Phase 4	Nov 13, 2023	Aalborg University
NCT05693545	Phase 2	Sep 1, 2023	Uganda Heart Institute, University of Cincinnati
NCT05303402	Phase 3	May 12, 2022	Asphalion, FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Laboratorios Hipra, S.A., Veristat, Inc.
NCT04083417	Phase 4	Sep 30, 2019	Government of Sweden, Linkoping University, Lund University, Umea University
NCT04084106	Phase 4	Sep 12, 2019	Uppsala University
NCT03847610	Phase 1	Apr 12, 2018	Imperial College London
NCT03326661	N/A	Nov 10, 2017	University of Southern Denmark
NCT02922686	Phase 4	Dec 1, 2016	Health Research Board, Ireland, Mater Misericordiae University Hospital, Mercy University, National University of Ireland, Royal College of Surgeons, Ireland
NCT02712307	Phase 4	Sep 1, 2015	Government of Sweden, Lund University, Public Health Agency of Sweden
NCT02185209	Phase 4	Mar 1, 2015	Karolinska Institute
NCT03208361	Phase 3	Nov 5, 2013	Jordi Gol i Gurina Foundation
NCT01499875	Phase 1	Jan 1, 2012	Aarhus University
NCT01368341	Phase 4	Jun 1, 2011	Government of Norway, Norwegian University of Life Sciences, Sorlandet Hospital HF, University of Oslo
NCT00823433	Early Phase 1 (Phase 1)	Jan 1, 2009	United States Army

Showing 14 of 14 trials

Page 1 / 1

Organizations

Research & Development (29)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Government of Sweden	Government	2	1	1	2015
Lund University	Academic/Hospital	2	0	1	2015
Aalborg University	Academic/Hospital	1	1	1	2023
Aarhus University	Academic/Hospital	1	1	1	2012
Asphalion	For profit	1	0	1	2022
FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA	Academic/Hospital	1	0	1	2022
Government of Norway	Government	1	0	1	2011
Health Research Board, Ireland	Academic/Hospital	1	0	1	2016
Imperial College London	Academic/Hospital	1	1	1	2018
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta	Academic/Hospital	1	0	1	2022
Jordi Gol i Gurina Foundation	Academic/Hospital	1	1	1	2013
Karolinska Institute	Academic/Hospital	1	1	1	2015
Laboratorios Hipra, S.A.	For profit	1	1	1	2022
Linkoping University	Academic/Hospital	1	0	1	2019
Mater Misericordiae University Hospital	Academic/Hospital	1	0	1	2016
Mercy University	Academic/Hospital	1	0	1	2016
National University of Ireland	Academic/Hospital	1	0	1	2016
Norwegian University of Life Sciences	Academic/Hospital	1	0	1	2011
Public Health Agency of Sweden	Academic/Hospital	1	1	1	2015
Royal College of Surgeons, Ireland	Academic/Hospital	1	1	1	2016

29 organizations

Page 1 / 2

Marketing (21)

Organization	Org type	Relationship	Date
American Antibiotics	For profit	MKTG	Nov 17, 1971
American Home Products	For profit	MKTG	Jan 13, 1958
American Home Products	For profit	NDA	—
Apothecon	For profit	MKTG	Mar 8, 1971
Aurobindo Pharma	For profit	MKTG	Apr 29, 2008
Belcher Pharmaceuticals	For profit	MKTG	Nov 17, 1971
Bristol-Myers	For profit	MKTG	—
Chartwell Pharmaceuticals	For profit	MKTG	Nov 23, 1988
DAVA Pharmaceuticals	For profit	MKTG	Nov 23, 1988
Eli Lilly	For profit	MKTG	Apr 7, 1967
GlaxoSmithKline	For profit	MKTG	Aug 12, 1980
Hikma	For profit	MKTG	Oct 11, 2013
Lederle	For profit	MKTG	—
Mylan	For profit	MKTG	Aug 7, 1972
Parke-Davis	For profit	MKTG	—
Pfizer	For profit	MKTG	Aug 9, 1974
Pharmacia & Upjohn	For profit	MKTG	—
Puracap Pharmaceutical	For profit	MKTG	Oct 28, 1976
Sandoz	For profit	MKTG	Nov 30, 1995
Strides Pharma Science	For profit	MKTG	Nov 23, 1988
Teva	For profit	MKTG	Jul 3, 1968